CD44 expressed on cancer-associated fibroblasts is a functional molecule supporting the stemness and drug resistance of malignant cancer cells in the tumor microenvironment.
about
Direct Interaction between Carcinoma Cells and Cancer Associated Fibroblasts for the Regulation of Cancer InvasionCancer stem cells and the tumor microenvironment: interplay in tumor heterogeneityBroad targeting of angiogenesis for cancer prevention and therapyCarcinoma-associated fibroblasts: orchestrating the composition of malignancyTargeting gallbladder cancer: oncolytic virotherapy with myxoma virus is enhanced by rapamycin in vitro and further improved by hyaluronan in vivo.Serglycin in tumor microenvironment promotes non-small cell lung cancer aggressiveness in a CD44-dependent manner.Extreme low dose of 5-fluorouracil reverses MDR in cancer by sensitizing cancer associated fibroblasts and down-regulating P-gpFibroblast heterogeneity in the cancer wound.Translational horizons in the tumor microenvironment: harnessing breakthroughs and targeting cures.Fibroblast-Derived Exosomes Contribute to Chemoresistance through Priming Cancer Stem Cells in Colorectal Cancer.The HSP90 Inhibitor Ganetespib Radiosensitizes Human Lung Adenocarcinoma Cells.Heterogeneity of Cancer Stem Cells: Rationale for Targeting the Stem Cell Niche.Peritoneal tumor spread in serous ovarian cancer-epithelial mesenchymal status and outcomeActivated human mesenchymal stem/stromal cells suppress metastatic features of MDA-MB-231 cells by secreting IFN-β.Liquid-based three-dimensional tumor models for cancer research and drug discovery.Notch4+ cancer stem-like cells promote the metastatic and invasive ability of melanoma.SFRP2 augments WNT16B signaling to promote therapeutic resistance in the damaged tumor microenvironmentThe Role of CD44 in Disease Pathophysiology and Targeted Treatment.Perspective of Targeting Cancer-Associated Fibroblasts in Melanoma.MtDNA depletion influences the transition of CD44 subtypes in human prostate cancer DU145 cells.The fibroblast surface markers FAP, anti-fibroblast, and FSP are expressed by cells of epithelial origin and may be altered during epithelial-to-mesenchymal transition.Evaluation of PSF1 as a prognostic biomarker for prostate cancer.Hyaluronan coated cerium oxide nanoparticles modulate CD44 and reactive oxygen species expression in human fibroblasts.PI3K/Akt/mTOR pathway dual inhibitor BEZ235 suppresses the stemness of colon cancer stem cells.Intratumoral accumulation of podoplanin-expressing lymph node stromal cells promote tumor growth through elimination of CD4+ tumor-infiltrating lymphocytesCD44+ fibroblasts increases breast cancer cell survival and drug resistance via IGF2BP3-CD44-IGF2 signalling.Gas6 derived from cancer-associated fibroblasts promotes migration of Axl-expressing lung cancer cells during chemotherapy.Elevated expression of Tie1 is accompanied by acquisition of cancer stemness properties in colorectal cancer.Metabolic shift toward oxidative phosphorylation in docetaxel resistant prostate cancer cellsEstablishment of oral squamous cell carcinoma cell line and magnetic bead-based isolation and characterization of its CD90/CD44 subpopulations.Sulforaphane reverses gefitinib tolerance in human lung cancer cells via modulation of sonic hedgehog signaling.Fibrocytes: A Novel Stromal Cells to Regulate Resistance to Anti-Angiogenic Therapy and Cancer Progression.Targeting tumor microenvironment to curb chemoresistance via novel drug delivery strategies.Heterotypic breast cancer model based on a silk fibroin scaffold to study the tumor microenvironment.Targeting the tumour stroma to improve cancer therapy.Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment.The role of tumor microenvironment in resistance to anti-angiogenic therapy.The biology and role of CD44 in cancer progression: therapeutic implications.PSF1 (Partner of SLD Five 1) is a Prognostic Biomarker in Patients with Non-small Cell Lung Cancer Treated with Surgery Following Preoperative Chemotherapy or Chemoradiotherapy.PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer.
P2860
Q26782289-3BF546F9-AFEE-4C09-A2C0-F53072E10C11Q26796292-21377B7C-C1ED-4B4E-A54A-15518D2BF9B0Q27002903-6B422203-8596-4318-9CC4-02266229E307Q28078667-F8CFDCC8-E6C3-41A9-8745-A31CBF4C96D5Q33613734-5FCC3B08-3000-4B24-A882-E43764EE7A61Q33635277-F3464685-88E4-4A1A-9006-2F589AE6D469Q33853293-FACD26F4-9FB4-4979-A44F-1CF7EB067818Q33964324-41E4DDDD-E52A-473A-ADE0-46FEA5F25B16Q35219539-0623E7FB-78D4-4D9A-84AE-902E9C6F2CBCQ35566486-6D564CF8-F27C-4D47-9FF4-DA6121FDF954Q35818450-2EE0B4FB-0EDD-46AC-8087-9816AAB6FE16Q36165598-532341F8-6FF2-4541-9CA2-527187E09907Q36232027-1C6CAF2C-F10B-410D-B3A4-FA052AE85568Q36866472-E78D8A41-955C-41AB-8D88-77BECB054A9DQ37107139-7E55D6F6-2DFF-4103-A78D-30B5EA795EC8Q37170715-DEB15D91-0D6E-4C3D-8F27-5BF5B87E76C0Q37195520-E80722D1-AB90-48C1-8B37-AE3B3869A7C8Q38466771-4DC5EF87-F689-4135-AB61-9D590608E9FBQ38549236-703416CC-CECE-4DE9-A2C8-2B4696BC8BF9Q38695440-B1B1FCC6-5DDB-4E35-8AE6-2F5D62F57BCDQ38708652-1D171701-DB83-4472-B653-24266B841DE7Q38939897-18A72F7B-63E6-4C7A-9FCD-738C9F8711BCQ39945487-9B4EA10C-7C88-4F6D-A67B-A175564B272BQ40509393-6BB92EE6-FE3C-4546-8E3C-1CCEFC8ECD9CQ41298234-60AD1E70-1533-4453-817A-E33022A54BB1Q41520586-719D7B60-EBC3-4FCD-A29F-CDA80BDF4ADDQ41631094-283E9D35-BCCD-409B-8D61-46A467C87CA4Q42215410-A494C229-4562-4516-B71E-3BE56517777EQ42250126-F2BDF549-FCC9-4770-BD60-2D3843652042Q42371627-7C4AA4A0-2422-4F61-8D9B-128B7B713838Q47097913-DDEB9B22-907F-4F4D-A6C0-D2F20B4E3413Q47668446-5188D6FC-2278-4209-B18C-C183DC2E32C6Q48308048-89FB332C-5B49-4717-9B6D-14D03398527EQ50043000-D5BE5609-EEE2-492D-A5B4-747B0704C743Q52322982-DAAA03E6-255C-402B-A4C9-AA43BEED596DQ52571378-72772C26-CD2F-4FD0-8762-40F2115DE7C6Q52645823-6332B868-B110-40D5-BE1A-ADA1AED60DAAQ54110894-8EA52252-F78A-44F9-8CDF-56920CE3B0EAQ54725286-5FD48813-63EF-4301-8608-2EF03EF3580AQ55518346-C28FFA86-9B67-41CA-99D7-DB0FDF37DECF
P2860
CD44 expressed on cancer-associated fibroblasts is a functional molecule supporting the stemness and drug resistance of malignant cancer cells in the tumor microenvironment.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
CD44 expressed on cancer-assoc ...... in the tumor microenvironment.
@en
CD44 expressed on cancer-assoc ...... in the tumor microenvironment.
@nl
type
label
CD44 expressed on cancer-assoc ...... in the tumor microenvironment.
@en
CD44 expressed on cancer-assoc ...... in the tumor microenvironment.
@nl
prefLabel
CD44 expressed on cancer-assoc ...... in the tumor microenvironment.
@en
CD44 expressed on cancer-assoc ...... in the tumor microenvironment.
@nl
P2093
P2860
P356
P1433
P1476
CD44 expressed on cancer-assoc ...... in the tumor microenvironment.
@en
P2093
Nobuyuki Takakura
Takahiro Matsui
Yumi Kinugasa
P2860
P304
P356
10.1002/STEM.1556
P577
2014-01-01T00:00:00Z